Cannabics Pharmaceuticals, Inc. (CNBX) Advances on Strength from Israel’s Thriving Medical Marijuana Industry

When you hear the words “medical marijuana” your mind is more likely to drift to California than Israel, but the medical marijuana industry in this small Mediterranean country is booming. Unlike in the United States, medical marijuana is legal nationwide in Israel and is estimated to be a $40 million industry with considerable growth.

The Israeli government plays a vital role in the industry’s growth and potential, supporting the research for breakthrough cannabis therapies. Cannabics Pharmaceuticals is taking advantage of this backing and is currently preparing to launch a series of clinical studies in Israel where the company’s research and development division is strategically located. Just last week Cannabics received Government Certification from the Ministry of Health, enabling the company to move forward with its plans to begin advanced laboratory medical research dedicated to cannabinoid science.

Through the course of its own research to date, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for physicians and patients wishing to utilize the unique medical properties of the cannabis plant.

With an aim of being one of the first and few companies to commercialize clinically tested cannabis-based medical products, Cannabics is developing cannabinoid-based anti-cancer therapies starting with its Cannabics SR capsules. The capsules contain a pure concentrate of cannabinoids derived from select cannabis strains. In observational studies, these IP pending medical cannabis capsules provided beneficial therapeutic effects for 10-12 hours upon a single oral administration.

Cannabics will utilize its new laboratory to continue its advanced research program to demonstrate cannabinoids’ potential as a viable source of anti-cancer therapies.

“The exciting scientific field of cannabinoid research has been largely neglected throughout most of the 20th Century due to a total ban on this field of research,” Cannabics CEO Dr. Zohar Koran stated in an earlier news release announcing the certification. “Thus, the available scientific knowledge regarding active cannabinoids and their mechanisms of action in various disease pathways is dramatically lacking in comparison to other therapeutic fields. There is a huge space of uncharted territory to explore with regards to the potential therapeutic roles of this class of compounds for diverse indications.”

Cannabics’ broader plan is to leverage the vast opportunities for research and development in Israel and launch its SR products under existing medical cannabis regulatory pathways in eligible states of the US and EU markets while simultaneously beginning its clinical studies.

For more information, visit www.cannabics.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net